Whether you are a health system exploring new ways to ensure optimal care for patients with cancer or a biopharma company looking to accelerate your precision oncology pipeline, get in touch to learn how Strata can help.
Beyond genomics
Guiding the next wave of precision oncology innovation
Using conventional comprehensive genomic profiling, only a fraction of patients have a molecular profile that has an actionable therapeutic match.
We’re leading the way by combining DNA and quantitative RNA profiling on a single small sample to expand treatment selection beyond genomic alteration-targeted therapies to gene expression-based therapies.
Using highly quantitative RNA and novel, multivariate predictive treatment selection algorithms, we have the potential to double the actionability of molecular profiling and improve outcomes for more patients than ever before.
Comprehensive genomic profiling (CGP) alone
CGP + quantitative RNA-based prediction algorithms
Proportion of patients with compelling treatment hypothesis
Source: Strata Oncology internal data
Strata Select
Our flagship molecular profiling test includes the following:
- Immunotherapy Response Score
- Genomic Signatures (TMB and MSI)
- Comprehensive Genomic Profiling
Treatment Response Scores
In addition to the Immunotherapy Response Score, Strata Select also offers additional novel, multivariate biomarkers as supplemental information. Strata Treatment Response Scores are based on the expression of multiple genes analyzed via quantitative RNA sequencing.
Antibody-drug Conjugate Treatment Response Scores
- Predictive biomarkers for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs); based on a proprietary calculation method of three components including ADC target expression
Angiogenesis Inhibitor Treatment Response Score
- A multi-gene expression algorithm that integrates multiple angiogenesis related target genes chosen based on co-expression patterns across VEGFR TKI responsive and resistant tumor types
Interested in leveraging Strata Treatment Response Scores for drug development?
Gene Expression Scores
Analytically and clinically validated gene expression results analyzed via quantitative RNA sequencing of individual genes that may be useful for correlating with treatment response to approved or investigational therapies. Biomarker results may also confer eligibility for clinical trials.
Homologous recombination deficiency (HRD)
Strata assesses genomic instability simultaneously with BRCA1/BRCA2 alterations to define HRD status. HRD reporting is provided for all Strata Select ovarian tests.